Literature DB >> 12490128

[Drug resistance and genotyping of Klebsiella pneumoniae in lower respiratory tract infection].

Jinling Shi1, Yan Li, Congrong Li, Xuan Cai, Hongxia Li, Shaohua Peng.   

Abstract

OBJECTIVE: To understand the current drug resistance of Klebsiella pneumoniae in lower respiratory tract infection and the prevalence trend of extended spectrum beta-lactamase (ESBLs)-producing Klebsiella pneumoniae.
METHODS: Drug resistance in 86 strains of Klebsiella pneumoniae and ESBLs-producing strains were genotyped by randomly amplified DNA polymorphisms (RAPD).
RESULTS: ESBLs-producing strains accounted for 20.9% of the 86 strains, and 83.3% of the ESBLs-producing strains were from respiratory ICU. The drug resistance rate of ESBLs positive bacteria was much higher than that of ESBLs negative bacteria. ESBLs positive bacteria were resistant to both the quinolones and a minoglylosides. Eighteen ESBLs-producing strains were divided into 12 types. 3 strains had the same profile (genotype A), and 5 strains had an identical profile (genotype B), but other strains had different profiles.
CONCLUSIONS: Chromosomal DNA analysis proved that certain types of ESBLs-producing Klebsiella pneumoniae were epidemic in respiratory ICU. RAPD was an economic, simple but reliable method in epidemic study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490128

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  2 in total

1.  The Prevalence of ESBLs Producing Klebsiella pneumoniae Isolates in Some Major Hospitals, Iran.

Authors:  Sobhan Ghafourian; Zamberi Bin Sekawi; Nourkhoda Sadeghifard; Reza Mohebi; Vasantah Kumari Neela; Abbas Maleki; Ali Hematian; Mohammad Rhabar; Mohammad Raftari; Reza Ranjbar
Journal:  Open Microbiol J       Date:  2011-08-16

2.  Analysis of diverse β-lactamases presenting high-level resistance in association with OmpK35 and OmpK36 porins in ESBL-producing Klebsiella pneumoniae.

Authors:  Hasan Ejaz
Journal:  Saudi J Biol Sci       Date:  2022-02-25       Impact factor: 4.052

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.